Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review
H Gong, SC Ong, F Li, Y Shen, Z Weng, K Zhao… - Health Economics …, 2024 - Springer
Since 2017, immune checkpoint inhibitors (ICIs) have been available for the treatment of
advanced hepatocellular carcinoma (HCC) or unresectable HCC, but their adoption into …
advanced hepatocellular carcinoma (HCC) or unresectable HCC, but their adoption into …
Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses
Background Atezolizumab (ATZ) plus bevacizumab (BVC) co-administration is one of the
newest systemic interventions in advanced hepatocellular carcinoma (AHCC). This …
newest systemic interventions in advanced hepatocellular carcinoma (AHCC). This …
Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
Z Zheng, Y Lin, H Cai - Frontiers in Public Health, 2024 - frontiersin.org
Objective The goal of this study is to compare the cost-effectiveness of tislelizumab and
sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. Methods A …
sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. Methods A …
First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis
G **ang, Y Huang, N Zhang, X Du… - Clinical Medicine …, 2024 - journals.sagepub.com
Background: Hepatocellular carcinoma poses a significant public health burden in China,
necessitating the economic evaluation of new therapeutic strategies for policy-makers and …
necessitating the economic evaluation of new therapeutic strategies for policy-makers and …
Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
H Cai, J Lin, H Zhu, Z Zheng - BMJ open, 2024 - bmjopen.bmj.com
Aim The objective of this research is to assess the cost-effectiveness of combining
camrelizumab with rivoceranib in comparison to sorafenib as first-line therapeutic options for …
camrelizumab with rivoceranib in comparison to sorafenib as first-line therapeutic options for …
Hepatocellular carcinoma and AIM2: Therapeutic potential through regulation of autophagy and macrophage polarization
S **e, C Wang, X Liu, C Li, J Yu, S Ma… - Immunity …, 2024 - Wiley Online Library
Objective Hepatocellular carcinoma (HCC) poses a significant challenge to global health. Its
pathophysiology involves interconnected processes, including cell proliferation, autophagy …
pathophysiology involves interconnected processes, including cell proliferation, autophagy …
Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China
S Luo, S Lai, Y Wu, J Hong, D Lin, S Lin… - Strahlentherapie und …, 2024 - Springer
Background Bevacizumab shows superior efficacy in cerebral radiation necrosis (CRN)
therapy, but its economic burden remains heavy due to the high drug price. This study aims …
therapy, but its economic burden remains heavy due to the high drug price. This study aims …
Promising first‐line immuno‐combination therapies for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
F Wen, P Huang, Q Wu, Y Yang, K Zhou… - Cancer …, 2024 - Wiley Online Library
Abstract Background and Aims Hepatocellular carcinoma (HCC) is one of the leading
causes of cancer‐related death all over the world, and brings a heavy social economic …
causes of cancer‐related death all over the world, and brings a heavy social economic …
Sora's Potential Influence on the Marketing Industry
Abstract In February 2024, Sora, a new groundbreaking Generative Artificial Intelligence
(GAI), was launched, which has the ability to generate clear, smooth, high-quality and …
(GAI), was launched, which has the ability to generate clear, smooth, high-quality and …
Atezolizumab and Bevacizumab Combination in Advanced Hepatocellular Carcinoma; A Systematic Review of Economic Evaluations
G Mohammadnezhad, H Esmaily, M Talebi, M Jafari - 2023 - researchsquare.com
Background: Atezolizumab (ATZ) plus bevacizumab (BVC) co-administration is one of the
newest systemic interventions in advanced hepatocellular carcinoma (AHCC). This …
newest systemic interventions in advanced hepatocellular carcinoma (AHCC). This …